UK pharmaceutical company Shire has announced a deal to acquire US biotech firm NPS Pharmaceuticals.
The acquisition will see Shire pay $5.2 billion (£3.4 billion) in cash amounting to $46 per share price and is a 51 per cent premium to the US company's share price of $30.47 on December 16th. Shire stated that it would be using its cash resources as well as new bank facilities to ensure that the transaction can be completed.
Shire has been looking to make an acquisition in recent months. In October the company failed in a bid to purchase US drug firm AbbVie. Members of the AbbVie board recommended that shareholders voted against a £32 billion takeover bid from Shire stating that the introduction of tax changes had introduced an "unacceptable level of uncertainty".
Plans had been put in place to situate the newly merged company in Jersey but these had to be abandoned after AbbVie called time on the deal. As a result, Shire's share price dipped by 11 per cent, on top of a 22 per cent drop seen following the announcement.
Following that disappointment, Shire has been on the lookout for other opportunities and the purchase of NPS Pharmaceuticals has been heralded as a major coup for the company. The boards of both firms has approved the deal and is expected to include Shire's earnings from 2016.
Flemming Ornskov, Shire's chief executive, said: "The acquisition of NPS Pharma is a significant step in advancing Shire's strategy to become a leading biotechnology company. This is about growth and rare diseases, and it fits hand in glove with our strategy and our franchise."
Shire's ability to secure a deal for NPS Pharmaceuticals provided a slight boost to its share price which was up 0.06 per cent at 4,744 at 09:33 GMT on Monday (January 12th).
Find up to date information on the FTSE 100 and spread betting strategies at City Index.
GAIN Capital UK Limited (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.
No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.